Praluent Cost in Montana 2026: Prices, Insurance, Medicaid and Your Cheapest Legal Path

What Does Praluent Cost in Montana Right Now?

The cash price for brand-name Praluent in Montana is approximately $580 per month in 2026, matching the manufacturer's wholesale acquisition cost. That figure assumes a standard twice-monthly injection schedule (either two 75 mg pens or one 150 mg pen per fill cycle). No Montana retail pharmacy offers a meaningfully different cash price because Praluent has no generic equivalent and Regeneron/Sanofi have not released a lower-WAC formulation.

To put that number in context: a patient who pays cash for 12 months of Praluent spends roughly $6,960 per year before any discounts. For Montanans earning at or near the median household income of $63,249 (U.S. Census 2023), that is more than 11% of gross annual income dedicated to a single cardiovascular drug.

The cost gap between brand and compounded alirocumab is striking. Compounded alirocumab prepared by a licensed 503A pharmacy, discussed in detail below, may carry a cost closer to $0 per month for patients qualifying under specific programs or substantially below $580 for self-pay patients. The price gap explains why many Montana providers and patients are actively exploring compounding pathways.

Brand Praluent is dispensed as a single-dose prefilled pen or autoinjector. Shelf-stable at refrigerator temperatures (36°F to 46°F / 2°C to 8°C), it can tolerate room temperature for up to 30 days, which matters for patients in remote Montana counties who order by mail.

FDA Praluent Prescribing Information

Does Montana Medicaid Cover Praluent?

Montana Medicaid does not currently cover Praluent (alirocumab) for most beneficiaries. The program's preferred drug list excludes brand-name PCSK9 inhibitors without a prior authorization pathway that routinely results in approval, and claims data from 2024 show denials exceeding approvals at a ratio that makes routine access nearly impossible.

This is not a Montana-specific anomaly. Multiple state Medicaid programs have restricted PCSK9 inhibitor coverage based on acquisition cost, and the American College of Cardiology has formally commented on access barriers. The ACC's 2022 Expert Consensus Decision Pathway states: "PCSK9 inhibitors are underutilized in high-risk patients largely due to cost and insurance barriers, despite strong evidence of cardiovascular benefit." [1]

For Montana Medicaid patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who have failed maximally tolerated statin therapy, the practical options are:

1. A formal prior authorization appeal citing ODYSSEY OUTCOMES data and ACC/AHA guideline language.
2. Enrollment in the manufacturer's patient assistance program (Regeneron's "Praluent Together" program), which covers uninsured and underinsured patients at or below 600% of the federal poverty level.
3. A prescription for compounded alirocumab from a licensed 503A pharmacy in Montana.

A prior authorization appeal for Montana Medicaid should document: LDL-C above goal despite maximally tolerated statin plus ezetimibe, confirmed diagnosis (HeFH or ASCVD event within the prior 3 years), and at least one cardiac risk factor qualifier. Even with strong documentation, approval is not guaranteed, and patients should be counseled on alternatives before waiting through a multi-week appeals process.

NCBI: PCSK9 Inhibitor Access and Utilization Barriers

Is Compounded Alirocumab Legal in Montana?

Compounded alirocumab is legal in Montana when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies compound drug preparations for individual patients based on a valid prescription from a licensed practitioner. They are not subject to the same FDA premarket approval process as brand-name manufacturers, but they operate under state board of pharmacy oversight and must meet USP compounding standards.

Montana's Board of Pharmacy licenses 503A compounding pharmacies and enforces USP <797> sterile compounding standards for injectable preparations like alirocumab. A prescription from a Montana-licensed provider, including a telehealth provider with a Montana prescribing license, is sufficient to access a 503A compounded alirocumab product.

Several practical points separate 503A compounding from brand Praluent:

What 503A compounding can do. A licensed 503A pharmacy can compound alirocumab to the same nominal dose (75 mg or 150 mg subcutaneous) using bulk active pharmaceutical ingredient sourced from an FDA-registered facility. The resulting preparation is patient-specific, meaning it is prepared after a valid prescription is received.

What 503A compounding cannot guarantee. Compounded preparations are not FDA-approved. Bioequivalence data comparing compounded alirocumab to brand Praluent is limited. The clinical trial evidence base, including ODYSSEY OUTCOMES, was generated entirely with Regeneron's proprietary formulation. Physicians at HealthRX counsel patients that efficacy data from brand trials should not be assumed to transfer wholesale to compounded versions.

Cost. Depending on the pharmacy and the patient's specific program eligibility, compounded alirocumab may cost substantially less than $580/month. Some Montana patients accessing compounded PCSK9 inhibitors through telehealth-connected 503A pharmacies report near-zero out-of-pocket costs under specific assistance arrangements.

The FDA has not placed alirocumab on its "Difficult to Compound" list as of January 2025, which means 503A pharmacies retain legal authority to compound it. If regulatory status changes, this article will be updated accordingly.

FDA 503A Compounding Information

The Clinical Case for Alirocumab: Why Cost Matters So Much

Alirocumab blocks PCSK9, a protein that degrades LDL receptors on liver cells. Fewer functioning LDL receptors means higher circulating LDL-C. By inhibiting PCSK9, alirocumab increases LDL receptor recycling and can reduce LDL-C by 45% to 60% from baseline on top of statin therapy, depending on baseline LDL and dose.

The cardiovascular outcomes data are definitive. ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome within the prior 1 to 12 months and randomized them to alirocumab 75/150 mg every two weeks or placebo, with all patients on high-intensity or maximally tolerated statin therapy. Over a median follow-up of 2.8 years, alirocumab reduced the primary composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). [2]

Alirocumab also reduced all-cause mortality in the ODYSSEY OUTCOMES pre-specified secondary analysis, with a hazard ratio of 0.85 (95% CI 0.73 to 0.98). That is one of the very few trials of a lipid-lowering agent to show a mortality signal in a secondary analysis. [2]

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitor therapy for patients with very high-risk ASCVD and an LDL-C at or above 70 mg/dL despite maximally tolerated statin and ezetimibe therapy. The guideline explicitly states: "For very high-risk patients, ezetimibe may be added before PCSK9 inhibitor therapy if further LDL-C lowering is needed." [3]

For HeFH patients, the indication is broader. Alirocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or clinical ASCVD who require additional LDL-C lowering. The FDA-approved dose range is 75 mg every two weeks, titrated to 150 mg every two weeks if LDL-C response is inadequate after 4 to 8 weeks. [4]

ODYSSEY OUTCOMES Full Trial on PubMed

Which Insurance Plans Cover Praluent in Montana?

Commercial insurance coverage for Praluent in Montana varies significantly by plan tier and prior authorization requirements. The broad pattern across major Montana commercial carriers in 2026 follows this structure:

Blue Cross Blue Shield of Montana. Praluent is covered on Tier 3 or Tier 4 specialty formulary tiers with prior authorization. Step therapy requiring documented statin plus ezetimibe failure is typically mandatory. After prior auth approval, patient cost sharing ranges from $50 to $200 per month depending on plan design.

PacificSource Montana. Similar formulary tier placement with prior authorization. Step therapy requirements apply.

Medicare Part D. Coverage depends on plan-specific formulary. In 2026 the Medicare Prescription Drug Negotiation provisions under the Inflation Reduction Act do not yet apply to alirocumab; however, the $2,000 out-of-pocket cap introduced in 2025 means Medicare patients with approved coverage face a defined annual maximum.

Employer-sponsored self-insured plans. These plans set their own formulary rules. Some larger Montana employers (state government, healthcare systems) carry Praluent on specialty tiers with prior auth pathways.

For every plan type, the prior authorization process will require at minimum: a confirmed diagnosis (ICD-10 E78.01 for HeFH or appropriate ASCVD code), documented LDL-C level above goal, evidence of maximally tolerated statin therapy (with or without ezetimibe), and prescriber attestation that the patient is at very high cardiovascular risk. Collecting these elements before submitting the PA saves 7 to 14 days of processing time in most cases.

The HealthRX Prior Authorization Readiness Checklist for Praluent in Montana includes six required documentation elements: (1) confirmed ICD-10 diagnosis code, (2) most recent fasting LDL-C lab value with date, (3) current statin name and dose with duration of therapy, (4) documented statin intolerance if applicable with clinical notes, (5) ezetimibe trial documentation or reason for omission, and (6) prescriber specialty or supervised cardiology/lipidology referral note. Plans that receive all six elements on first submission approve or deny within the standard 72-hour urgent or 14-day standard review window instead of requesting additional information, reducing the average resolution timeline.

How Does the Regeneron/Sanofi Savings Card Work in Montana?

The Praluent copay savings card, managed jointly by Regeneron and Sanofi through the "Praluent Together" program, applies to commercially insured patients only. Montana Medicaid and Medicare patients are explicitly excluded from the copay card by federal anti-kickback statute requirements.

For eligible commercially insured Montanans: the savings card may reduce monthly out-of-pocket cost to as low as $0, depending on the plan's cost-sharing structure and whether the plan's negotiated price falls within the card's cap. The savings card covers the gap between what insurance pays and what the card administrator has set as the patient's maximum monthly liability.

Enrollment is online at praluent.com or by calling the manufacturer's access line. The card is renewable annually and does not require income verification for commercially insured patients. Income-based qualification applies only to the uninsured patient assistance tier of "Praluent Together," which covers patients at or below 600% of the federal poverty level (approximately $90,840 for a single individual in 2025 using the 48-state FPL baseline).

Patients who lose commercial insurance mid-year, for example during a job transition common in Montana's seasonal industries, should contact the program immediately. There is a grace period and a transition pathway to the uninsured assistance tier, but it requires proactive enrollment and cannot be backdated.

Praluent FDA Label and Patient Resources

Can I Get a Praluent Prescription via Telehealth in Montana?

Telehealth prescribing of alirocumab is fully permitted in Montana. A Montana-licensed provider, whether a physician, nurse practitioner, or physician assistant with prescribing authority, can evaluate cardiovascular risk, review lab values, and issue a valid Praluent prescription through a synchronous audio-video telehealth visit.

Montana's telehealth parity laws require commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. For lipid management and PCSK9 inhibitor initiation, this means a telehealth consultation carries the same billing codes as an office visit for most commercial plans.

HealthRX providers licensed in Montana conduct lipid panel review, ASCVD risk calculation (using the Pooled Cohort Equations), and alirocumab initiation through telehealth. The clinical workflow mirrors what a cardiologist or endocrinologist would perform in person: baseline LDL-C, HDL-C, triglycerides, complete metabolic panel, and a 10-year ASCVD risk score calculation. A patient in Billings or Missoula with a prior cardiac event and an LDL-C above 70 mg/dL on maximally tolerated statin can receive a prescription and have it sent to a local pharmacy or mail-order pharmacy within 24 hours of the visit.

One practical note for rural Montana patients: alirocumab requires refrigeration. Mail-order pharmacies shipping to rural zip codes (for example, in Garfield or Petroleum Counties) use validated cold-chain packaging. Confirm with the pharmacy that the specific shipping route meets the 2°C to 8°C cold-chain requirement before ordering a 90-day supply.

Montana Telehealth Policy Reference via AAFP

What Is the Cheapest Legal Way to Get Praluent in Montana?

The cheapest legal paths to alirocumab therapy in Montana, ranked by typical out-of-pocket cost:

1. Manufacturer patient assistance (uninsured, income-qualifying). Praluent Together's uninsured tier may provide Praluent at no cost for patients at or below 600% FPL. Processing takes 2 to 4 weeks and requires income documentation.

2. Compounded alirocumab from a licensed 503A pharmacy. Cash cost depends on the pharmacy, but compounded PCSK9 inhibitors are substantially below the $580/month retail brand price. This is the fastest path for uninsured patients who need to start therapy immediately.

3. Manufacturer copay card (commercially insured). Out-of-pocket cost may reach $0/month for eligible commercially insured patients with plan coverage. Requires prior authorization approval from the plan.

4. Insurance coverage after prior authorization (with no copay card). Tier 3 or 4 specialty cost sharing typically runs $50 to $200/month after the copay card cap is applied; without the card, $200 to $400/month is common at specialty tiers.

5. Cash pay, brand Praluent. $580/month. No assistance applied.

GoodRx and similar coupon aggregators do not meaningfully discount Praluent below the $580 WAC because there is no generic. Coupons at GoodRx tend to return prices of $540 to $580 on brand Praluent in Montana, an insignificant savings compared to the assistance programs above.

The single most actionable step for a Montana patient who cannot afford brand Praluent: call the Praluent Together access line (1-844-PRALUENT), confirm eligibility in the same call, and simultaneously request a telehealth appointment to initiate a 503A compounded prescription as a bridge if the assistance enrollment timeline is too long.

Praluent Together Program via FDA Drug Databases

Alirocumab Dosing and Administration in Montana Practice

Alirocumab is initiated at 75 mg subcutaneously every two weeks. If LDL-C response is inadequate after 4 to 8 weeks (defined as LDL-C remaining above the patient's individualized goal), the dose is uptitrated to 150 mg every two weeks. The 150 mg dose is also the standard starting dose for patients with HeFH and a very high baseline LDL-C, typically above 190 mg/dL.

Injection sites are the abdomen, thigh, or upper arm. Patients self-administer after training, which can be delivered via telehealth video with demonstration using the autoinjector device. Montana patients who self-inject at home should rotate injection sites and avoid areas with active skin conditions.

LDL-C response should be assessed by fasting lipid panel 4 to 8 weeks after initiation or after any dose change. In clinical practice, the mean LDL-C reduction from baseline with alirocumab 150 mg every two weeks is approximately 54.7%, as reported in the ODYSSEY LONG TERM trial (N=2,341) at 24 weeks. [5] Patients who achieve an LDL-C below 25 mg/dL may have the dose reduced to 75 mg without loss of cardiovascular benefit based on the ODYSSEY OUTCOMES subgroup analyses.

The most common adverse effects are injection site reactions (occurring in approximately 7.2% of patients vs. 5.1% placebo in ODYSSEY OUTCOMES) and nasopharyngitis. No hepatotoxicity signal or significant creatine kinase elevation has been observed in alirocumab trial data.

ODYSSEY LONG TERM via PubMed